NCT00320255 - A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

ThrombosisCancerPulmonary Embolism

Interventions

DRUG

Apixaban

Oral tablets administered once daily in 5-, 10-, or 20-mg dose

DRUG

Placebo

Oral tablets administered once daily

Trial Locations (14)

Memorial Sloan-Kettering Cancer Center, New York

Mount Sinai School Of Medicine, New York

University Of Rochester, Rochester

University Of Texas Md Anderson Cancer Ctr, Houston

Arizona Cancer Center, Tucson

Nevada Cancer Institute, Las Vegas

Univ. Of Southern Calif. /Norris Comprehensive Cancer Center, Los Angeles

Dana-Farber Cancer Inst, Boston

Local Institution, Hamilton

Local Institution, London

Local Institution, Toronto

Local Institution, Toronto

Local Institution, Montreal

Local Institution, Montreal